<DOC>
	<DOCNO>NCT00054574</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody ABX-EGF locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness ABX-EGF treating patient prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical effect monoclonal antibody ABX-EGF , determine PSA response , patient hormone-resistant prostate cancer rise PSA value without metastasis . - Determine pharmacokinetics safety profile ( include immunogenicity ) drug patient . - Determine overall survival patient treated drug . - Determine time disease progression time PSA progression patient treat drug . OUTLINE : This multicenter study . Patients receive monoclonal antibody ABX-EGF IV 1 hour weekly . Treatment continue every 8 week 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year . PROJECTED ACCRUAL : Approximately 30-50 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis prostate cancer rise PSA value without metastasis PSA must least 5 ng/mL PSA must show increase reference level 2 separate occasion Must tumor overexpressing epidermal growth factor receptor ( EGFr ) immunohistochemistry Staining must 2+ 3+ least 10 % evaluated tumor cell Must tissue available diagnostics Must fail prior frontline luteinizing hormonereleasing hormone ( LHRH ) analogue ( e.g. , leuprolide goserelin ) OR fail orchiectomy castrate level testosterone ( le 50 mg/mL ) NOTE : Must continue LHRH analogue ( unless orchiectomy perform ) throughout study PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count great 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN AST ALT great 3 time ULN Renal Creatinine le 2.2 mg/dL Calcium great ULN Cardiovascular Left ventricular ejection fraction least 45 % MUGA No myocardial infarction within past year Other HIV negative Fertile patient must use effective contraception 1 month study No malignancy within past 5 year except basal cell carcinoma No history chronic medical psychiatric condition laboratory abnormality would preclude study participation , administration , interpretation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy See Disease Characteristics At least 6 week since prior steroidal nonsteroidal antiandrogens ( 4 week flutamide ) Concurrent steroid therapy allow replacement therapy Radiotherapy Not specify Surgery See Disease Characteristics Other At least 30 day since prior investigational therapy At least 30 day since prior anticancer therapy No prior systemic therapy prostate cancer ( except hormonal therapy ) No prior antiEGFr therapy Concurrent antihypercalcemic treatment allow presence elevate calcium level cancer therapy bone disease No concurrent antiEGFr therapy No concurrent anticancer therapy No concurrent investigational therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>